SAR-260301 is primarily investigated for its potential therapeutic applications in the field of oncology. It functions as a selective inhibitor of PI3K-beta, a key enzyme involved in the PI3K/AKT/mTOR signaling pathway, which is often dysregulated in various cancers. By targeting this pathway, SAR-260301 aims to inhibit tumor growth and proliferation, particularly in cancers with PTEN deficiencies, where PI3K-beta plays a critical role. Preclinical studies have shown promising results in reducing tumor progression, making it a candidate for further development in cancer treatment strategies. Its specificity for PI3K-beta also suggests potential for minimizing off-target effects, which could improve therapeutic outcomes and reduce side effects compared to broader PI3K inhibitors.